News

The transaction involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site. The facility consists of more than 200,000 square feet for laboratories,

A-CUBE, a venture capital backed company (funded by JAIC and Ben du Pont’s yet2ventures.com), uses proprietary in silico algorithms to develop various monoclonal antibodies and candidate DNA vaccines

The company posted a net loss of $4.3m, compared to a net loss of $1.47m for the same period in 2009. Titan Pharma’s loss from operations was $3.98m,

The agreement has been signed by Sanofi-aventis with the laboratory of Gerard Karsenty to evaluate the role of osteocalcin, osteoblast-secreted peptide in diabetes management. As per the agreement,

GSK claims Solabegron is a highly selective and potent beta3-adrenoceptor agonist which is in development for the reduction of symptoms of overactive bladder (OAB) and irritable bowel syndrome

Earlier, Mersana Therapeutics has released data from a Phase 1 trial evaluating XMT-1001, which showed high and prolonged plasma levels of XMT-1001 active release products and a safety

Takeda, along with its wholly owned subsidiary, Tianjin Takeda Pharmaceuticals expects to increase its sales force up to approximately 900 in China. The new company will be responsible

The tie up allows Sanofi-aventis to develop a platform for ophthalmology so as to introduce more solutions for patients where unmet therapeutic needs remain, Pharmabiz reported. Under the

Avodart prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. GSK said that it will withdraw applications from regulatory review where procedures are ongoing and, in